← Leaderboards
James Forrest Kirk
Nanotherapeutics, Inc.
$1,785,738
Attributed
$3,571,476
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $998K · FY2011–15$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$3,571,476 · 1
By mechanism
R44$3,571,476 · 1
Top collaborators
- Yawei Ni5 shared
Most similar at Nanotherapeutics, Inc.
Same institution · by research overlap
- Yawei Ni$3,837,115
- James David Talton$15,179,333
- Barbel Eppler$100,816
- Ronald Cobb$296,331
Others in their field
Top investigators on “Acids”
- Eric S Lander · Whitehead Institute For Biomedical Res$346,225,799
- Richard A Gibbs · Baylor College Of Medicine$207,450,549
- Robert H Waterston · Washington University$167,167,875
- Richard K. Wilson · Washington University$108,492,348
- Michael P Snyder · Yale University$79,863,532
- Kristin Ardlie · Genomics Collaborative, Inc.$59,282,753
Research focus
AcidsAdjuvantAgonistAnimal ModelAnimalsAntigensAntiviral AgentsArizonaBaseCaliciviridaeCenters For Disease Control And Prevention (U.S.)ChildClinical ResearchClinical TrialsCyclic GmpDesignDeveloping CountriesDisease OutbreaksDrug FormulationsEpidemicFamilyFoodborne OutbreakGastroenteritis5 Year Old
Grant awards (5)
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$997,966
R44 · FY2015 · AI · contact PI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$997,804
R44 · FY2014 · AI · contact PI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$996,995
R44 · FY2013 · AI · contact PI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$289,356
R44 · FY2012 · AI · contact PI
GelVac Stable, Dry-Powder Nasal Recombinant VLP-Based Bivalent Norovirus Vaccine$289,355
R44 · FY2011 · AI · contact PI